NO983823L - FremgangsmÕte og preparat for inhibering av irreversible celleforandringer pÕ grunn av stress - Google Patents

FremgangsmÕte og preparat for inhibering av irreversible celleforandringer pÕ grunn av stress

Info

Publication number
NO983823L
NO983823L NO983823A NO983823A NO983823L NO 983823 L NO983823 L NO 983823L NO 983823 A NO983823 A NO 983823A NO 983823 A NO983823 A NO 983823A NO 983823 L NO983823 L NO 983823L
Authority
NO
Norway
Prior art keywords
stress
preparation
changes due
compounds
cellular changes
Prior art date
Application number
NO983823A
Other languages
English (en)
Norwegian (no)
Other versions
NO983823D0 (no
Inventor
Guy Miller
Lillian Lou
John Nakamura
Original Assignee
Galileo Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galileo Lab Inc filed Critical Galileo Lab Inc
Publication of NO983823D0 publication Critical patent/NO983823D0/no
Publication of NO983823L publication Critical patent/NO983823L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO983823A 1996-02-23 1998-08-20 FremgangsmÕte og preparat for inhibering av irreversible celleforandringer pÕ grunn av stress NO983823L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/607,022 US5801159A (en) 1996-02-23 1996-02-23 Method and composition for inhibiting cellular irreversible changes due to stress
PCT/US1997/002945 WO1997030713A1 (fr) 1996-02-23 1997-02-20 Procede et composition pour inhiber les modifications cellulaires irreversibles dues au stress

Publications (2)

Publication Number Publication Date
NO983823D0 NO983823D0 (no) 1998-08-20
NO983823L true NO983823L (no) 1998-10-01

Family

ID=24430472

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983823A NO983823L (no) 1996-02-23 1998-08-20 FremgangsmÕte og preparat for inhibering av irreversible celleforandringer pÕ grunn av stress

Country Status (7)

Country Link
US (1) US5801159A (fr)
EP (1) EP0935466A1 (fr)
JP (1) JP2000506834A (fr)
AU (1) AU1974997A (fr)
CA (1) CA2247461A1 (fr)
NO (1) NO983823L (fr)
WO (1) WO1997030713A1 (fr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6338963B1 (en) 1994-07-25 2002-01-15 Neotherapeutics, Inc. Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis
US6339073B1 (en) * 1997-09-11 2002-01-15 Oxigene, Inc. Uses of nicotinamide adenine dinucleotide and its derivatives for treatment of malignant and infectious diseases
AU3786299A (en) 1998-05-04 1999-11-23 Neotherapeutics, Inc. Novel serotonin-like 9-substituted hypoxanthine and methods of use
DK0951842T3 (da) * 1999-01-20 2003-01-06 Nutricia Nv Ernæringsprodukt til et spædbarn
US6426362B1 (en) 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
US6528042B1 (en) 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US6288069B1 (en) 1999-11-16 2001-09-11 Neotherapeutics, Inc. Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue
US6407237B1 (en) 2001-02-21 2002-06-18 Neotherapeutics, Inc. Crystal forms of 9-substituted hypoxanthine derivatives
US6849735B1 (en) * 2000-06-23 2005-02-01 Merck Eprova Ag Methods of synthesis for 9-substituted hypoxanthine derivatives
WO2002004448A2 (fr) 2000-07-07 2002-01-17 Neotherapeutics, Inc. Procedes de traitement de neuropathie peripherique induite par des medicaments et etats associes
US7034054B2 (en) * 2000-12-15 2006-04-25 Galileo Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
US6759427B2 (en) 2001-04-20 2004-07-06 Spectrum Pharmaceuticals, Inc. Synthesis and methods of use of tetrahydroindolone analogues and derivatives
US20030133918A1 (en) * 2001-07-10 2003-07-17 Sherley James L. Methods for ex vivo propagation of somatic stem cells
AU2003228212A1 (en) * 2002-02-15 2003-09-09 Gracy G. Crane Hepatocyte precursor cell lines
EP1352910A1 (fr) 2002-04-10 2003-10-15 Grünenthal GmbH Nouveaux derives d'analogues de nitrobenzylthioinosine
DE60325353D1 (de) * 2002-05-21 2009-01-29 Abbott Lab Behandlung von mukositis
US20050009788A1 (en) * 2002-07-29 2005-01-13 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling connexin 43 expression
US7320997B2 (en) * 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US7763649B2 (en) * 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US20050026874A1 (en) * 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US7521584B2 (en) * 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US20050059659A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
US7145025B2 (en) * 2002-07-29 2006-12-05 Hawaii Biotech, Inc. Structural carotenoid analogs for the inhibition and amelioration of disease
US7375133B2 (en) * 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US7345091B2 (en) * 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US7723327B2 (en) * 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US20050049248A1 (en) * 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
AU2003287574A1 (en) * 2002-11-07 2004-06-03 Rensselaer Polytechnic Institute Calmodulin independent activation of nitric oxide synthase by nadph analogs
US7199110B2 (en) * 2002-12-30 2007-04-03 Purdue Research Foundation Method of treatment for spinal cord injury
CA2580584C (fr) 2003-09-19 2015-07-28 Galileo Pharmaceuticals, Inc. Utilisation d'alpha-tocotrienol pour le traitement de maladies mitochondriales
WO2005102356A1 (fr) * 2004-04-14 2005-11-03 Hawaii Biotech, Inc. Analogues ou derives de carotenoide pour inhiber et reduire l'inflammation
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US7423144B2 (en) * 2004-05-26 2008-09-09 Inotek Pharmaceuticals Corporation Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof
US7655465B2 (en) * 2004-06-07 2010-02-02 Massachusetts Institute Of Technology Methods for ex vivo propagation of somatic hair follicle stem cells
US20050276762A1 (en) * 2004-06-15 2005-12-15 Tapas Das Topical compositions containing 5'-adenosine-diphosphate ribose
JP4724810B2 (ja) * 2005-03-02 2011-07-13 財団法人ヒューマンサイエンス振興財団 ポリ（ａｄｐ−リボース）代謝のバイオマーカーとしてのリボシルアデノシンおよびリボシルイノシン
EP1874289A2 (fr) 2005-03-29 2008-01-09 Cardax Pharmaceuticals, Inc. Reduction de l'activation du complement et de l'inflammation dans une lesion tissulaire a l'aide de carotenoides, d'analogues de carotenoides ou de derives de carotenoides
CA2610152C (fr) 2005-06-01 2018-04-10 Edison Pharmaceuticals, Inc. Medicaments pouvant subir une oxydo-reduction destines au traitement des maladies mitochondriales et d'autres affections et modulation de biomarqueurs relatifs a l'etat energetique
WO2007002228A1 (fr) * 2005-06-23 2007-01-04 Massachusetts Institute Of Technology Methodes de propagation ex vivo de cellules souches hepatiques adultes
ITRM20050391A1 (it) * 2005-07-22 2007-01-23 Giuliani Spa Composti analoghi della 6-tioguanosina trifosfato, loro uso in campo medico e procedimento per la loro preparazione.
EA019675B1 (ru) 2006-02-22 2014-05-30 Эдисон Фармасьютикалз, Инк. Редокс-активные терапевтические средства для лечения митохондриальных заболеваний и модуляции биомаркера коэнзима q
EP2004139A1 (fr) * 2006-03-31 2008-12-24 Adenobio N.V. Compositions, procédés, et trousses utilisant l'adénosine et l'inosine combinées pour un diagnostic et un traitement
EP3018122B1 (fr) 2007-11-06 2018-10-10 BioElectron Technology Corporation Dérivés de 4- (p-quinolyl) -2-hydroxybutanamide pour le traitement de maladies mitochondriales
CA2708961C (fr) 2008-01-08 2017-03-28 Ptc Therapeutics, Inc. Derives de (het)aryl-p-quinone pour le traitement de maladies mitochondriales
WO2009111576A2 (fr) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. Dérivés de p-quinone 2-substituée pour le traitement de maladies de stress oxydatif
WO2009158348A1 (fr) * 2008-06-25 2009-12-30 Edison Pharmaceuticals, Inc. Dérivés 2-hétérocyclylaminoalkyl-(p-quinone) pour traiter les maladies liées à un stress oxydatif
BRPI0918139B1 (pt) 2008-09-10 2024-04-30 Ptc Therapeutics, Inc Composição, alimento medicinal ou funcional, suplemento alimentar ou dietético para tratamento de distúrbios de desenvolvimento pervasivos com terapêuticos redox-ativos
CA2740773A1 (fr) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Traitement d'affections liees au stress oxydatif, notamment de la nephropathie aux produits de contraste, des radiolesions et des perturbations de la fonction des globules rouges
CN102264730B (zh) 2008-10-28 2016-04-13 爱迪生药物公司 用于生产生育三烯酚及衍生物的方法
JP2012525399A (ja) 2009-04-28 2012-10-22 エジソン ファーマシューティカルズ， インコーポレイテッド トコトリエノールキノンを用いる、レーバー遺伝性視神経症および優性遺伝性視神経萎縮症の治療
SI2470168T1 (en) * 2009-08-26 2018-05-31 Bioelectron Technology Corporation Procedures for the prevention and treatment of brain ischemia
LT2523669T (lt) 2010-01-11 2017-04-25 Inotek Pharmaceuticals Corporation Akispūdžio mažinimo būdas, derinys ir rinkinys
AU2011230580A1 (en) 2010-03-26 2012-10-11 Inotek Pharmaceuticals Corporation Method of reducing intraocular pressure in humans using N6 -cyclopentyladenosine (CPA), CPA derivatives or prodrugs thereof
EP2601287B1 (fr) 2010-08-05 2015-01-07 Amgen Inc. Dipeptides pour améliorer le rendement et la viabilité de cultures cellulaires
JP2014520894A (ja) 2011-07-19 2014-08-25 エジソン ファーマシューティカルズ， インコーポレイテッド 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法
PL2807178T3 (pl) 2012-01-26 2017-12-29 Inotek Pharmaceuticals Corporation Bezwodne polimorfy azotanu (2R,3S,4R,5R)-5-(6-(cyklopentyloamino)-9H-puryn-9-ylo)-3,4-dihydroksytetrahydrofuran-2-ylo)metylu i sposoby ich wytwarzania
PL227045B1 (pl) * 2012-09-14 2017-10-31 Blirt Spółka Akcyjna Płyn do przechowywania narządów w czasie zabiegów chirurgicznych, zwłaszcza transplantacji.
WO2014152723A1 (fr) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Formulations ophtalmiques
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
WO2016100579A1 (fr) 2014-12-16 2016-06-23 Edison Pharmaceuticals, Inc., Formes polymorphes et amorphes de (r)-2-hydroxy-2-méthyl-4-(2,4,5-triméthyl-3,6-dioxocyclohexa-1,4-diényle)butanamide
WO2017106786A1 (fr) 2015-12-16 2017-06-22 Bioelectron Technology Corporation Procédés améliorés pour l'enrichissement en alpha-tocotriénol à partir de compositions de tocol mixtes
CN113024369A (zh) 2015-12-17 2021-06-25 Ptc医疗公司 用于治疗氧化应急障碍的化合物
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
JP7586815B2 (ja) 2018-10-17 2024-11-19 ピーティーシー セラピューティクス， インコーポレイテッド α－シヌクレイノパチー、タウオパチー、および他の障害を抑制および処置するための２，３，５－トリメチル－６－ノニルシクロヘキサ－２，５－ジエン－１，４－ジオン
CN118175991A (zh) 2021-07-08 2024-06-11 Ptc医疗公司 包含2,3,5-三甲基-6-壬基环己-2,5-二烯-1,4-二酮的药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4575498A (en) * 1983-07-21 1986-03-11 Duke University Method for restoring depleted purine nucleotide pools
US5066578A (en) * 1989-12-21 1991-11-19 The Regents Of The University Of California Long-term preservation of organs for transplantation
US5145771A (en) * 1990-04-12 1992-09-08 The University Of North Carolina At Chapel Hill Rinse solution for organs and tissues
US5320846A (en) * 1991-04-17 1994-06-14 New England Deaconess Hospital Corp. Method and composition for testing patients with metabolic depleting diseases
US5565317A (en) * 1992-06-26 1996-10-15 Torii Pharmaceutical Co., Ltd. Perfusion and storage solution containing sodium lactobionate, sodium dihydrogenphosphate, raffinose, glutathione, allopurinol and nafamostat mesylate
US5405742A (en) * 1993-07-16 1995-04-11 Cyromedical Sciences, Inc. Solutions for tissue preservation and bloodless surgery and methods using same

Also Published As

Publication number Publication date
JP2000506834A (ja) 2000-06-06
NO983823D0 (no) 1998-08-20
EP0935466A1 (fr) 1999-08-18
AU1974997A (en) 1997-09-10
WO1997030713A1 (fr) 1997-08-28
US5801159A (en) 1998-09-01
CA2247461A1 (fr) 1997-08-28

Similar Documents

Publication Publication Date Title
NO20081365L (no) Ny krystallinsk form av et pyridazino[4,5-b]indolderivat
WO2009086457A3 (fr) Dérivés de purine 6,9-disubstituée et leur utilisation en tant que produits cosmétiques et compositions cosmétiques
NO960049L (no) Fremstilling og stabilisering av celler
ES2176502T3 (es) Derivados de hidroxilamina utiles para mejorar la pproduccion de chaperonas moleculares su su preparacion.
KR20170102861A (ko) 식물 추출물의 혼합물 또는 상기 식물 속에 함유된 분자의 혼합물을 함유하는 조성물, 및 당질 및/또는 지질 대사를 조절하기 위한 용도
ES2048560T3 (es) Fibra dietetica, su procedimiento y composicion con actividad fisiologica que lo contiene como ingrediente activo.
DE60041637D1 (de) Augenbehandlung unter verwendung von cyclosporin a derivaten
FI960750A0 (fi) Hermon kasvutekijän farmaseuttiset formulaatiot
NO20005155L (no) Forbedring av antistoff-cytokin fusjon protein-medierte immunoresponser ved ko-administrasjon med angiogeneseinhibator
AR037971A1 (es) Preparacion liofilizada que contiene un anticuerpo contra el receptor egf
NO954878L (no) Pyrrolderivater
WO2002017898A3 (fr) Compositions et procedes visant a induire une vasorelaxation
Schramm et al. Natural products as potential human ether-a-go-go-related gene channel inhibitors–screening of plant-derived alkaloids
DK0563085T3 (da) Hidtil ukendte præparater
NO20056000L (no) Vevsbeskyttende cytokiner for beskyttelse, gjenoppbygging og okning av responsivceller, vev og organer med et utvidet terapeutisk vindu
KR960704561A (ko) 바이러스성 유발 종양의 예방과 치료용 조성물
FR2612775A1 (fr) Compositions pour la prevention et le traitement de la degenerescence cutanee
DK0673250T3 (da) Ophthalmiske præparater omfattende emedastin og deres anvendelse til behandling af allergisk conjunctivitis
NO941097L (no) Hudregenererende kosmetisk preparat
DK578789D0 (da) Pyrrolidin-2-carboxylsyre-derivater med psykotrop virkning, deres fremstilling og anvendelse
Wu et al. Cardiac effects of the extract and active components of radix stephaniae tetrandrae: I. Electrically-induced intracellular calcium transient and protein release during the calcium paradox
ATE481976T1 (de) Zusammensetzungen aus organischen extrakten von geum japonicum thunb var. und ihre verwendung
Van Belle et al. The effect of calcium antagonists and of mioflazine on the release of purine nucleosides after 10 min of ischemia in the iated guinea pig heart
WO2002078600A3 (fr) Composition a base de peptide $g(c)$g(e)rack et procede de protection contre les dommages des tissus dus a l'ischemie
Pestre et al. Effect of bepridil treatment on myocardial susceptibility to global ischemia in chronically infacrted rat hearts

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application